| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/14/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 07/31/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/26/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/05/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.9% stake in enVVeno Medical Corporation |
| 01/31/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/06/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
4
| Jenusaitis Matthew (Director) has filed a Form 4 on enVVeno Medical Corp|
Txns:
| Granted 8,403 options
@ $6.7, valued at
$56.3k
|
|
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/01/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/27/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/16/2022 |
4
| Gray Robert (Director) has filed a Form 4 on enVVeno Medical Corp|
Txns:
| Exercised 1,041 restricted stock units
@ $0 |
|
| 09/16/2022 |
4
| Jenusaitis Matthew (Director) has filed a Form 4 on enVVeno Medical Corp|
Txns:
| Exercised 1,041 restricted stock units
@ $0 |
|
| 08/18/2022 |
4
| Duhay Francis (Director) has filed a Form 4 on enVVeno Medical Corp|
Txns:
| Bought 7,751 shares
@ $6.14, valued at
$47.6k
|
|
| 08/03/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/01/2022 |
4
| Shrivastava Sanjay (Director) has filed a Form 4 on enVVeno Medical Corp|
Txns:
| Bought 1,000 shares
@ $3.85, valued at
$3.9k
|
|
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
UPLOAD
| Form UPLOAD - SEC-generated letter: |
| 05/11/2022 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 05/11/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 05/11/2022 |
CORRESP
| Form CORRESP - Correspondence: |
| 05/06/2022 |
UPLOAD
| Form UPLOAD - SEC-generated letter: |
| 04/29/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/18/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.9% stake in enVVeno Medical Corporation |
| 02/14/2022 |
SC 13G/A
| CVI Investments, Inc. reports a 2.9% stake in enVVeno Medical Corporation |
| 02/11/2022 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 4.4% stake in enVVeno Medical Corporation |
|